Jinling Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Jinling Pharmaceutical has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.9% per year. Jinling Pharmaceutical's return on equity is 1.6%, and it has net margins of 2.5%.
Key information
0.5%
Earnings growth rate
-0.02%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 2.9% |
| Return on equity | 1.6% |
| Net Margin | 2.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jinling Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,902 | 73 | 425 | 101 |
| 30 Jun 24 | 2,855 | 74 | 424 | 89 |
| 31 Mar 24 | 2,824 | 100 | 429 | 86 |
| 31 Dec 23 | 2,786 | 100 | 424 | 79 |
| 30 Sep 23 | 2,721 | 110 | 412 | 71 |
| 30 Jun 23 | 2,760 | 124 | 401 | 82 |
| 31 Mar 23 | 2,686 | 110 | 386 | 79 |
| 01 Jan 23 | 2,671 | 105 | 385 | 74 |
| 30 Sep 22 | 2,752 | 116 | 379 | 63 |
| 30 Jun 22 | 2,739 | 104 | 383 | 54 |
| 31 Mar 22 | 2,800 | 125 | 385 | 60 |
| 01 Jan 22 | 2,809 | 121 | 383 | 57 |
| 30 Sep 21 | 2,796 | 85 | 393 | 54 |
| 30 Jun 21 | 2,783 | 117 | 380 | 47 |
| 31 Mar 21 | 2,692 | 128 | 351 | 41 |
| 31 Dec 20 | 2,504 | 65 | 328 | 44 |
| 30 Sep 20 | 2,413 | -13 | 306 | 45 |
| 30 Jun 20 | 2,389 | -58 | 303 | 47 |
| 31 Mar 20 | 2,435 | -93 | 324 | 45 |
| 31 Dec 19 | 2,535 | 145 | 349 | 44 |
| 30 Sep 19 | 2,532 | 359 | 343 | 34 |
| 30 Jun 19 | 2,623 | 380 | 375 | 30 |
| 31 Mar 19 | 2,721 | 405 | 392 | 29 |
| 01 Jan 19 | 2,899 | 242 | 427 | 34 |
| 30 Sep 18 | 3,032 | 113 | 521 | 49 |
| 30 Jun 18 | 3,046 | 126 | 489 | 60 |
| 31 Mar 18 | 3,152 | 141 | 496 | 53 |
| 31 Dec 17 | 3,192 | 137 | 479 | 39 |
| 30 Sep 17 | 3,391 | 170 | 410 | 18 |
| 30 Jun 17 | 3,481 | 171 | 431 | 0 |
| 31 Mar 17 | 3,540 | 175 | 439 | 0 |
| 31 Dec 16 | 3,579 | 180 | 444 | 0 |
| 30 Sep 16 | 3,526 | 200 | 459 | 0 |
| 30 Jun 16 | 3,462 | 202 | 443 | 0 |
| 31 Mar 16 | 3,379 | 199 | 459 | 0 |
| 31 Dec 15 | 3,221 | 208 | 446 | 0 |
| 30 Sep 15 | 3,061 | 197 | 430 | 0 |
| 30 Jun 15 | 2,958 | 204 | 437 | 0 |
| 31 Mar 15 | 2,849 | 214 | 426 | 0 |
| 31 Dec 14 | 2,772 | 197 | 407 | 0 |
| 30 Sep 14 | 2,781 | 196 | 429 | 0 |
| 30 Jun 14 | 2,708 | 183 | 410 | 0 |
| 31 Mar 14 | 2,639 | 166 | 382 | 0 |
| 31 Dec 13 | 2,606 | 156 | 378 | 0 |
Quality Earnings: 000919 has a large one-off gain of CN¥31.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 000919's current net profit margins (2.5%) are lower than last year (4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000919's earnings have grown by 0.5% per year over the past 5 years.
Accelerating Growth: 000919's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000919 had negative earnings growth (-33.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 000919's Return on Equity (1.6%) is considered low.